XLONasdaqPharmaceutical PreparationsFiscal year ends December 31

Xilio Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$8.33−0.22 (-2.57%)

Close on Oct 19, 2026

Market cap: $161.64M
P/E (TTM): –
Dividend yield: –

Xilio Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	44	6.34	–	–	–	–
Research & Development	56	41	52	59	51	44
General & Administrative	30	25	27	30	24	11
Operating Expenses	86	67	79	89	75	55
Operating Income	-42	-61	-79	-89	-75	-55
Other Non-Operating Income	6.95	2.34	2.73	0.93	-0.76	-0.66
Merger & Restructuring Charges	–	0.94	–	–	–	–
Gain (Loss) on Sale of Assets	–	0.00	0.00	0.00	-0.02	–
Pretax Income	-35	-58	–	–	–	–
Income Tax Expense	0	0	0	0	0	0
Net Income incl. Noncontrolling Interests	-35	-58	-76	-88	-76	-55
Net Income	-35	-58	-76	-88	-76	-55
EPS (Basic)(per share)	-4.19	-15.24	-38.92	-45.08	-189.28	-1,475.88
EPS (Diluted)(per share)	-4.19	-15.24	-38.92	-45.08	-189.28	-1,475.88
Shares Outstanding (Basic, Weighted)(shares)	8.36	3.82	1.96	1.96	0.40	0.04
Shares Outstanding (Diluted, Weighted)(shares)	8.36	3.82	1.96	1.96	0.40	0.04
EBITDA	-40	-59	-77	-87	-74	-53

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -48.9%
Net margin: -34.1%
Return on equity, FY2025: -132.5%

Financial strength

Current ratio: 4.25
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 397.8%

Valuation

P/E ratio: –
Price to sales: 2.52
Price to book: 2.24
Dividend yield: –